Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA
Quick Facts
- Publication title: Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA
- Journal: Front Oncol
- Year: 2025
- DOI: 10.3389/fonc.2025.1659708
- PMID/PMCID: 41244896; PMC12615177
Research overview
The study prospectively collected plasma samples and clinical data of newly diagnosed multiple myeloma (NDMM) patients and healthy controls (HCs). This project establishes a plasma exosomal miRNA-based system for diagnosing multiple myeloma(MM) and evaluating patient prognosis, aiming to provide novel strategies for diagnosis and early warning in high-risk MM patients.
Key findings
In a validation cohort of 130 MM patients, we developed a prognostic nomogram that amalgamated the expression levels of three key exosomal miRNAs (hsa-miR-193b-5p, miR-483-3p, and let-7b-5p) with critical clinical variables, which exhibits superior performance compared to the ISS staging system.
This integrative model effectively predicted 1-, 3-, and 5-year survival probabilities, thereby stratifying patients into distinct risk categories for enhanced clinical decision-making and personalized follow-up strategies.
Study design
The study prospectively collected plasma samples and clinical data of newly diagnosed multiple myeloma (NDMM) patients and healthy controls (HCs).
Plasma samples were obtained in MM patients before the administration of any chemotherapy.
The study comprises three stages to identify plasma exosomal miRNAs associated with the diagnosis and prognosis of MM.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, miRNA profiling/sequencing and bioinformatic analysis, qPCR validation; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, qPCR Validation, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA Frontiers in oncology. 2025. DOI: 10.3389/fonc.2025.1659708. PMID/PMCID: 41244896; PMC12615177.